Immuron Limited (DE:ANW)

Immuron Limited (ANW) Stock Price & Analysis


ANW Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€0.03 - €0.11
Previous Close€0.05
Average Volume (3M)N/A
Market Cap
Enterprise Value-€3.50M
Total Cash (Recent Filing)AU$17.16M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)
Aug 30, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
Shares Outstanding227,998,346
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
Financial Highlights & Ratios
Price to Book (P/B)0.85
Price to Sales (P/S)20.72
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-6.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0




What was Immuron Limited’s price range in the past 12 months?
Immuron Limited lowest stock price was €0.03 and its highest was €0.11 in the past 12 months.
    What is Immuron Limited’s market cap?
    Currently, no data Available
    When is Immuron Limited’s upcoming earnings report date?
    Immuron Limited’s upcoming earnings report date is Aug 30, 2024 which is in 72 days.
      How were Immuron Limited’s earnings last quarter?
      Immuron Limited released its earnings results on Feb 28, 2024. The company reported -€0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.006.
        Is Immuron Limited overvalued?
        According to Wall Street analysts Immuron Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Immuron Limited pay dividends?
          Immuron Limited does not currently pay dividends.
          What is Immuron Limited’s EPS estimate?
          Immuron Limited’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Immuron Limited have?
          Currently, no data Available
          What happened to Immuron Limited’s price movement after its last earnings report?
          Immuron Limited reported an EPS of -€0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 33.333%.
            Which hedge fund is a major shareholder of Immuron Limited?
            Currently, no hedge funds are holding shares in DE:ANW

            Company Description

            Immuron Limited

            Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
            Similar Stocks
            Price & Change
            BioArctic AB Class B
            Popular Stocks
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis